|

Patient-derived Organoids of Lung Cancer to Test Drug Response

RECRUITINGSponsored by University Hospital, Geneva
Actively Recruiting
SponsorUniversity Hospital, Geneva
Started2019-04-01
Est. completion2026-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03979170

Summary

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically proven lung cancer
* Age ≥ 18
* Written informed and signed consent
* Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion Criteria:

* Less than 18 years of age
* Not able to give informed consent (language, intellectual capacities, etc.)
* Not accessible to biopsy and/or surgery sample
* Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

Conditions3

CancerLung CancerOrganoid

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.